# Thierry Façon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thierry-facon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 62,446 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 115 |
| i10-index | 444 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5024315315 |
| ORCID iD | https://orcid.org/0000-0001-7705-8460 |
| Works | 952 |

## Researcher papers

- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study](https://scholariq.org/papers/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)
- [A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial](https://scholariq.org/papers/a-simplified-frailty-scale-predicts-outcomes-in-transplant-ineligible-patients/)
- [Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial](https://scholariq.org/papers/maintenance-with-daratumumab-or-observation-following-treatment-with-bortezomib/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.